Download - Ex- Summary 1st Half 2012
-
7/31/2019 Ex- Summary 1st Half 2012
1/51
EXECUTIVE SUMMARY REPORTPakistan Pharmaceutical Market
The report is for the exclusive use of the recipient and may not be reproduced in anyform without the written consent from IMS. The information contained in the report isconfidential and may not be divulged to any other party. Copyright IMS AG, ZUGSwitzerland 2011
1st HALF 2012
-
7/31/2019 Ex- Summary 1st Half 2012
2/51
2
Executive Summary Report
Pharmaceutical Market
-
7/31/2019 Ex- Summary 1st Half 2012
3/51
3
TABLE OF CONTENTS
Foreword by Dr. Aman Ullah Khan 04
World market
Company News in Brief 06 Global Pharmaceutical Sales 17
Pakistan Pharmaceutical Market
Market Overview 18Commentary 33Medical Index of PAKISTAN facts ..40
Tables 43
Clients Feedback Form
FEEDBACK FORM 51
-
7/31/2019 Ex- Summary 1st Half 2012
4/51
4
FOREWORD
We are once again proud to present you the 1st semester of 2012
Executive Summary report based on Q2 2012 with analyses of thePakistan market. The importance of this report has been highlighted by
our respected clients who have time and again requested for this report.
IMS Health has always offered accurate, authentic & valuable market
insights to the Pharmaceutical industry through this report and has playedan important role in delineating the industry trends.
We would however, appreciate your valuable comments in the attachedfeedback form enabling us to further improve the quality and contents of
this report.
Yours Sincerely,
Dr. Aman Ullah Khan
Chief Executive
Tel Off: 021-34315148 / 34383700
E-mail: [email protected]
-
7/31/2019 Ex- Summary 1st Half 2012
5/51
5
WORLD MARKET
-
7/31/2019 Ex- Summary 1st Half 2012
6/51
6
January 2012
Corporate Developments
Both the EMA and FDA approved Sanofi/Genzymes Framingham manufacturingplant, allowing production of Fabry disease therapy Fabrazyme to recommence.Thirteen major manufacturers began an alliance with the WHO and non-profitorganisations to provide free treatments for neglected tropical diseases.
Actavis said it would shake up the global diabetes market via the formationof a joint venture with Bioton for the development of insulins, includinganalogue insulins.
Following its acquisition of Nycomed, Takeda said it would be consolidating itsR&D sites, changing to a more diverse portfolio focused on new products, andlaying off approximately 2,800 employees (2,100 in Europe and 700 in the US);the plan is expected to reduce income by 35bn in the financial year to March2012. Novartis is cutting 2,000 jobs in the US linked to the patent expiry oftop-seller Diovan this September and will take a $900m charge related to
reduced sales expectations for newer antihypertensive Tekturna/Rasilez. Itannounced an agreement to resolve the US class action litigation regardingunpaid over-time by sales representatives, providing up to $99m to be sharedamongst eligible class members.
Johnson & Johnson agreed to pay $158m to settle a case regarding thealleged improper marketing of antipsychotic Risperdalin Texas. The companywas also reported to be changing the executives in charge of its Tylenolunit(McNeil Consumer Healthcare), following the string of recalls in 2011.GlaxoSmithKline was fined by an Argentine court for failing to obtain properparental consent during a trial of pneumonia vaccine Synflorix.
Mergers & Acquisitions
Amgen entered into a $3.6bn merger agreement with Micromet, a German/USbiotech with a Phase II antibody for haematological malignancies, while Bristol-Myers Squibb is to acquire Inhibitex for $2.5bn, to expand its presence in thehepatitis C market. Watson bought Strides Arcolabs Australian and south-east Asian generics business, Ascent Pharmahealth.
Roche made a $44.50 per share offer for Illumina, valuing the DNA
sequencing and diagnostics firm at $5.7bn; the bid was hostile, following anumber of rebuffs from Illuminas management. Two days later, Illuminaadopted a shareholder rights plan but after Roche commenced its tender offerthe following day, Illuminas board of directors said it would review the offerand postpone its 2011 financial results announcements.
The tender offer will run until February 24th. Roche has also submitted fournominees for election to Illuminas board at its annual meeting.
-
7/31/2019 Ex- Summary 1st Half 2012
7/51
7
Product Issues
Novartis Consumer Health unit recalled a number of products, includingExcedrin and Bufferin, in the US because of the potential of foreign or brokentablets in the packs; the manufacturing problem also led to supply issues forEndos Opana ER and certain other analgesics.
Medivation and Pfizer announced further disappointing trial results for dimebonin Alzheimers disease and announced that they would be discontinuing itsdevelopment for all indications and terminating their collaboration.
-
7/31/2019 Ex- Summary 1st Half 2012
8/51
8
February 2012
Corporate Developments
Pfizer and Hisun advanced their memorandum of understanding to createHisun Pfizer Pharmaceutical Co. Ltd, a Chinese generics joint venture that willbe 51%-owned by Hisun. Merck & Co announced a new 51%-owned joint
venture with Supera Farma for the sale of innovative and branded genericproducts from Merck and Superas owners, Cristlia and Eurofarma, in Brazil.
US sales representatives filed an unpaid overtime suit against LEO Pharma.
Apotex paid Sanofi and Bristol-Myers Squibb $442m to satisfy the damagesruling following its launch of a generic version ofPlavixin 2006.
Mergers & Acquisitions
Illuminas board of directors unanimously rejected Roches $44.50 per sharecash tender offer as grossly inadequate. Nevertheless, later in the month Rocheextended the offer, which commenced on January 27th; Illumina noted that fewshares had been tendered.
Product Issues
Pfizer recalled its Lo/Ovraloral contraceptive and the generic equivalent in theUS due to incorrect packaging. Johnson & Johnson recalled another batch ofTylenol, this time the infants Oral Suspension 1oz grape formulation, aftersome users reported difficulties with the dosing system. Daiichi Sankyos
Luitpold subsidiary in the US recalled a batch of phenylephrine infectionfollowing the identification of visible particles.
Pfizer was sued by a group of plaintiffs who allege that taking its antidepressantZoloftwhilst pregnant caused birth defects in their children.
NGOs in India protested against Novartis attempts to patent its cancer drugGlivecin the country.
GSK paused enrolment in clinical trials ofAnacorsGSK 052 as a treatment for
complicated urinary tract infections due to a microbiological finding in a smallnumber of patients in one Phase IIb study.
-
7/31/2019 Ex- Summary 1st Half 2012
9/51
9
March 2012
Corporate Developments
Abbott announced that the pharmaceutical company created by its separationwould be known as AbbVie. Eisai is extending its UK headquarters to cover theEuropean, Middle Eastern and African business, while GlaxoSmithKline said it
would be investing 500m in the UK, building a new biopharmaceutical facilityin Cumbria and creating up to 1,000 new jobs partly in response to the Britishgovernments pledge to introduce a patent box, which would allow for a lowerrate of tax on profits generated by UK-based intellectual property. GSK andDaiichi Sankyo are creating a 50:50 vaccine development and marketing jointventure, known as Japan Vaccine Co., in Japan; it will begin operations in July.Conversely, Pfizer and Biocon decided not to pursue their biosimilar insulincommercialisation agreement, citing differences in individual priorities. Hospirareturned the US and Canadian rights to DurectsPosidur, a post-operative painrelief depot.
The US Department of Justice reportedly turned down a tentative $1bn federalsettlement with Johnson & Johnson over the alleged improper marketing ofits antipsychotic Risperdal; the company has already settled a case in Texas andtrials in other states are ongoing. A former Roche US sales manager won anage discrimation case against the company, while some sales representativesfiled an overtime suit against Novo Nordisk.
Mergers & Acquisitions
Sanofi is to purchase biosurgery company Pluromed, while Shire picked
FerroKin BioSciences, which has an iron chelator in Phase II trials. Valeantcontinued its acquisition trail, absorbing Natur Produkt, a Russian OTCmanufacturer; acquiring certain assets from Austrias Gerot Lannach (mainlybranded generics sold in Russia and the CIS); and taking a 19.9% stake in PeleNova, a Brazilian tissue regeneration biotechnology company.
Roche received a request for additional information on its hostile bid forIllumina from the FTC, and filed a definitive proxy statement before extendingits tender offer for a second time. It then increased its offer price from $44.50per share to $51, which Illuminas board said it would review. Amylin was
reported to have rejected a $3.5bn takeover offer from Bristol-Myers Squibb.
Product Issues
A US court dismissed an AstraZeneca lawsuit concerning the approval ofSeroquelcopies, as did the FDA with the companys Citizen Petition, and anumber of manufacturers launched generic quetiapine; AstraZenecasubsequently sued the FDA. Conversely, the US Seroquel XR formulation patent
-
7/31/2019 Ex- Summary 1st Half 2012
10/51
10
was found to be valid and infringed by a group of generics firms; this wasalso the case in the Netherlands, but in the UK the extended-release patent forthe antipsychotic was ruled to be invalid. In another setback, AstraZeneca saidit would not be pursuing the approval of TC-5214 as an adjunct therapy formajor depressive disorder; the product, licensed from Targacept, failed tomeet the primary endpoints of its latest Phase III studies. Endo filed anamended Citizen Petition trying to prevent the FDA approval of generic versions
of its topical analgesic for post-herpetic neuralgia, Lidoderm.
Sanofi began shipping Fabrazyme produced at its newly-approved plant inFramingham, MA, allowing US Fabry disease patients to return to full dosing;globally, normal supply levels should start to return in the second quarter.Simultaneously, Shire said it had decided to withdraw the BLA for its Fabrytherapy Replagal, after it appeared that the FDA would be requesting additionalclinical trials; it had been supplying Replagalto US patients, often free ofcharge, in response to Sanofis manufacturing deficiencies. Shire alsoannounced that Lialda (SPD476) had not shown efficacy as a treatment fordiverticulitis, so no regulatory filing was planned in this indication; the drug isalready marketed for ulcerative colitis.
British researchers are to examine whether GlaxoSmithKlines Pandemrix
pandemic flu vaccine might be linked to cases of narcolepsy in children. Bristol-Myers Squibb recalled organ storage fluid Viaspan in Europe owing to thepossibility of bacterial contamination. The FDA requested more information onEisais sNDA seeking approval ofDacogen as a treatment for acute myeloidleukaemia. An advisory panel voted against the approval ofMerck & Co andAriads ridaforolimus for sarcoma, citing a poor risk: benefit profile, and Mercksaid it would be discontinuing development of the oral formulation of
Cardiomes vernakalant for atrial fibrillation, based on an assessment of theregulatory environment and projected development timeline; work on theintravenous version (Brinavess) will continue.
-
7/31/2019 Ex- Summary 1st Half 2012
11/51
11
April 2012
Corporate Developments
Johnson & Johnson launched Janssen Therapeutics EMEA, a new Europeansubsidiary that will focus on the commercialization of TMC435 for hepatitis C,while Mylan is expanding its operations in Ireland. Novo Nordisk intends to
increase its US workforce by 15% this year, and Ipsen opened a newcommercial HQ in New Jersey. Meda announced that it had established anaffiliate in Hong Kong.
J&Js new CEO Alex Gorsky said he would be focusing on the recall problems atthe companys OTC unit, while AstraZeneca CEO David Brennan is making anabrupt departure in light of the firms recent poor performance.
Mergers & Acquisitions
It was a busy month for deal announcements, led by Watsons 4.25bnacquisition of Icelands Actavis, which could create the third-largest genericsmanufacturer. In smaller transactions, Amgen is to buy KAI, which has aPhase II candidate for secondary hyperparathyroidism, and Mustafa Nevzat ofTurkey; Takeda went for URL, which markets Colcrys for gout; andAstraZeneca is paying $1.26bn for Ardea, whose lead compound is also forgout. Valeants latest acquisition is Pedinol, a podiatry specialist, while Shirepicked up most of the assets ofPervasis, which has a regenerative medicineendothelial cell technology platform.
Human Genome Sciences rejected a $13 per share ($2.6bn) offer fromBenlysta partner GlaxoSmithKline, saying that it undervalued the company,but added that its board would be exploring strategic alternatives and that GSKhad been invited to participate in the process. Warner Chilcottdidnt identifyits potential suitors, but said it was also examining ways of enhancingshareholder value; Bayer was reported to be considering a bid. Pfizer divestedits nutrition business to Nestl, for $11.85bn.
After being rejected by both board and shareholders, Roche said it would notbe extending its tender offer for Illumina, or increasing the price of its $51 pershare ($6.8bn) hostile bid.
Product Issues
Novartis announced that a patient using its oral multiple sclerosis therapyGilenya had developed progressive multifocal leukoencephalopathy; however,the patient had previously used Biogen Idec and ElansTysabri, which isassociated with the rare viral disease.
-
7/31/2019 Ex- Summary 1st Half 2012
12/51
12
A few days later, the EMA concluded its review ofGilenyas safety, andrecommended stronger warnings; simultaneously, Novartis agreed to makesimilar changes to the products US label. The FDA placed Novartis hepatitis Ccandidate alisporivir on clinical hold following the death of a patient in a trial.
Bayer updated the US labels for its oral contraceptives containing drospirenone,regarding the higher risk of venous thromboembolism compared with products
using levonorgestrel or other progestins, while the FDA warned that Merck &Cos Propecia and Proscarfinasteride products, used for male pattern baldnessand benign prostatic hypertrophy respectively, might be associated with sexualside-effects.
Johnson & Johnson was ordered to pay a $1.1bn penalty by an Arkansas courtafter being found guilty of improperly marketing its antipsychotic Risperdal.
-
7/31/2019 Ex- Summary 1st Half 2012
13/51
13
May 2012
Corporate Developments
Abbott agreed to pay a total of $1.6bn to US federal and state authorities tosettle claims that it improperly promoted anticonvulsant Depakote for off-labelindications, and entered into a five-year Corporate Integrity Agreement. Pfizer
said it had reached an amicable settlement in the case brought by BrighamYoung University and Daniel Simmons, regarding the latters involvement in thedevelopment ofCelebrex: Pfizer will fund a chair at BYU in Simmons name. InFrance, a trial against Servier commenced concerning its now withdrawndiabetes drug Mediator, which has been linked to more than 500 deaths.
Endo Pharmaceutical Holdings shareholders approved a change in thecompanys name, to Endo Health Solutions, while Bayer was reported to beconsidering the sale of its Diabetes Care unit. Activist investor Carl Icahn isagain seeking to secure representatives on the Forest board of directors. Lilly
opened a new R&D centre in Shanghai, which will focus on diabetes.
The Indian government said officials at the countrys drug regulator had beencolluding with both domestic and international manufacturers to speed up drugapprovals, which sometimes meant products were not tested sufficiently.
Mergers & Acquisitions
Despite being rejected by the board in April, GlaxoSmithKline launched atender offer directly to Human Genome Sciences shareholders, promptingHGS to adopt a stockholder rights plan; GSK was later reported to be
considering a move to replace the entire HGS board of directors, and to extendits tender offer beyond June 7th.
Takeda announced an agreement to acquire Multilab, a Brazilian manufacturerof branded generic and over-the-counter drugs. Valeant bought certain assetsfrom Canadian nutraceutical firm Swiss Herbal Remedies, plus theAcneFreeskin treatment and other assets from University Medical of the US. Johnson& Johnson acquired Guangzhou Bioseal Biotechnology, which has a porcineplasma-derived product for the control of bleeding during surgery.
Product Issues
Daiichi Sankyo began a strategic collaboration with Coherus BioSciences forthe development and commercialisation ofEnbreland Rituxan/MabTherabiosimilars in Japan, South Korea and Taiwan.
After making a concerted effort to maintain sales following the loss of its USexclusivity last November, Pfizer told The Wall Street Journalthat it would no
-
7/31/2019 Ex- Summary 1st Half 2012
14/51
14
longer be negotiating new contracts to sell Lipitorto health plans, and also thatno advertising or sales force promotion for the drug would be continued;multiple generics were able to enter the US market on May 31. Pfizer alsoreported disappointing results for Lyrica in inadequately treated painful diabeticperipheral neuropathy, and halted a Phase III trial of the product for HIVneuropathy.
Sanofi and Bristol-Myers SquibbsPlavix, the worlds second best-sellingdrug after Lipitor, lost US exclusivity on May 17th. Onyx and Bayers Nexavar,marketed for liver and kidney cancers, did not improve overall survival in a non-small cell lung cancer trial, while Roche halted development of dalcetrapib aftersuggestions of lack of efficacy in a Phase III trial: it was designed to raise levelsof good HDL cholesterol.
The US National Institutes of Health is to work with AstraZeneca, Lilly andPfizer: the companies will make a number of their discontinued compoundsavailable to the NIH, which will investigate their potential in the treatment ofdifferent diseases. All the products target a specific gene, have already beenfound to be safe in humans, and any profits from commercialization would beshared.
-
7/31/2019 Ex- Summary 1st Half 2012
15/51
15
June 2012
Corporate Developments
Pfizer announced that would be running a partial IPO for its animal health unit,with the standalone company being known as Zoetis; separately, the patentexpiry ofLipitorwas linked to the company cutting 177 jobs in Ireland. Roche
is making 1,000 US employees redundant as part of a restructuring of its R&Doperations; some work will be transferred to Germany and Switzerland, and thehead of pharmaceutical research, Jean-Jacques Garaud, left the company.
Activist investor Carl Icahn continued his criticism of the executives at Forest,and sought to add more of his representatives to its board of directors.Johnson & Johnson said it would record a charge of $600m in the secondquarter related to the litigation over Risperdal, Invega, Natrecorand OmnicareInc. In a case involving GlaxoSmithKline but relevant to a number of othermajor pharmaceutical companies, the US Supreme Court ruled that the firm did
not owe its sales personnel overtime wages as they were exempt from a federalwage-and-hour law.
In China, a former researcher at WuXi PharmaTech was accused of stealingand selling two Merck & Co compounds his then company had been testing onbehalf of the US giant. The government introduced new legislation that couldsee it overrule patent protection in certain circumstances, and was reported tobe looking at doing so for Gileads antiretroviral tenofovir, a key component ofmany HIV treatment regimens.
Mergers & Acquisitions
Bristol-Myers Squibb is to buy diabetes specialist Amylin in a complicateddeal valuing the smaller firm at $5.3bn. BMS will pay out another $1.7bncomprising Amylins net debt and a contractual payment obligation to formerByetta partner Lilly, but in turn will receive $3.4bn from AstraZeneca, whichwill enter into a development and commercialisation collaboration with Amylinonce the acquisition has been completed. AstraZeneca, Novartis, Sanofi andMerck & Co had also reportedly been interested in Amylin, which recentlylaunched the extended-release exanatide product Bydureon in the US.
GSK again extended its $2.6bn tender offer to buy Benlysta partner HumanGenome Sciences,until June 29, despite the latters repeated rejection of thebid as being undervalued. Lilly CEO John Lechleiter again said he wasntinterested in any major acquisitions or diversification.
-
7/31/2019 Ex- Summary 1st Half 2012
16/51
16
Product Issues
Merck & Co and AstraZeneca amended their historical partnership relating to aformer US joint venture: AstraZeneca will not exercise its option to acquireMercks remaining interest in the joint venture in 2012, and will receive a newoption to do so in June 2014. The decision will boost Mercks revenue, thanks to
an interest in Nexium and Prilosec, by $200m annually. Merck KGaA began acollaboration with Dr Reddys for the development and commercialisation ofbiosimilars, with a focus on monoclonal antibodies for cancer.
Forest revised its 2013 earnings guidance downwards owing to a more severedrop in sales for antidepressant Lexapro than previously expected following theloss of US exclusivity in March. Amgen said Sensipar/Mimpara had not led to astatistically significant improvement in mortality/cardiovascular event rates inpatients with secondary hyperparathyroidism and chronic kidney disease ondialysis.
Sanofi Pasteur recalled all its BCG vaccine in Canada because of manufacturingproblems, while Novartis withdrew a batch of oral contraceptive Introvale owingto a packaging error. J&J is being sued over problems with its vaginal meshproducts. AstraZeneca halted a Phase I study of AZD2820, a subcutaneousmelanocortin-4 receptor partial agonist for obesity co-developed with Palatin,after one recipient suffered a serious adverse event, possibly an allergicreaction.
-
7/31/2019 Ex- Summary 1st Half 2012
17/51
GLOBAL MARKET SALES
Sales Through Retail Pharmacies (Twelve months to June 2012)
Total world Market $853.2 Bn
NORTH AMERICA $250.7 BnU.S.A. $231.1 Bn
CANADA $19.6 Bn
EUROPE $107.8 BnGERMANY $28 Bn
FRANCE $15.2 Bn
ITALY $28 BnSPAIN $13.9 Bn
UK $13.2 Bn
JAPAN (including hospitals) $102.2 Bn
CHINA (hospital) $45.3 Bn
LATIN AMERICA $41.3 BnBRAZIL $22.1 Bn
MEXICO $8.1 BnARGENTINA $5.3 Bn
AUSTRALIA/NZ $12 Bn
The top 5 therapy classes at ATC3 level in the 12 months to June 2012 were:
C10A-Cholesterol And Triglyceride Regulating preparations
A2B-Antiulcerants
N5A-Antipsychotics
N6A-Antidepressents & mood stabilizers
A10C-Human Insulin and Analogues
The top 5 products in the 12 months to June 2012 were:
1. Lipitor2. Crestor3. Plavix4. Seretide5. NexiumThe top 5 corporations in the 12 months to June 2012 were:
1. Pfizer2. Novartis3. Merck & Co4. AstraZeneca5. GlaxoSmithKline
-
7/31/2019 Ex- Summary 1st Half 2012
18/51
18
-
7/31/2019 Ex- Summary 1st Half 2012
19/51
19
MARKETOVERVIEW
The 1st Half 2012 saw a double digit growth for both MNCs and NATs. With the
market touching 180.083 billion Pak Rupees, the industry grew exceptionally
well with the phenomenal positive growth of+17.03% in MAT Q212. Nationals
continued to gain market share with a growth of +19.28% while Multinationals
also grew with a double digit growth of +14.24% (Q2 2012- MAT BASIS).
The fast onward march of the national companies continued capturing share of 56.40%,
leaving multinationals behind. Nationals also dominated unit market share with 52.64%
as compared to Multi-Nationals 47.36% (based on Q2 2012).
17.03
19.28
14.24
0.00
5.00
10.00
15.00
20.00
25.00
Q3-09
Q4-09
Q1-10
Q2-10
Q3-10
Q4-10
Q1-11
Q2-11
Q3-11
Q4-11
Q1-12
Q2-12
TOTAL NATIONAL MULTI-NATIONAL
VALUE WISE GROWTH LAST 12 QTRS - MAT BASIS
Growth
+/-
17.02
18.54
15.06
0.00
5.00
10.00
15.00
20.00
25.00
30.00
Q3-09
Q4-09
Q1-10
Q2-10
Q3-10
Q4-10
Q1-11
Q2-11
Q3-11
Q4-11
Q1-12
Q2-12
TOTAL NATIONAL MULTI-NATIONAL
VALUE WISE GROWTH LAST 12 QTRS - QTR BASIS
Growth
+/-
-
7/31/2019 Ex- Summary 1st Half 2012
20/51
20
NEW PRODUCT LAUNCHES
The past trend of National companies launching large number of New Products
continued during the first half of 2012.The value and total number of new products
launched by the industry in different segments/ ATC level I during Jan 2012 Jun 2012
are:
Value Number of New ProductsTOTAL 438,517,459 212
NATIONAL 380,741,787 196
MULTI-NATIONAL 57,775,672 16
-
7/31/2019 Ex- Summary 1st Half 2012
21/51
21
Month wise Products Launched
As per monthly activity in the industry in term of New Product launches, we can
see that March 2012 was the most active month with 57 launches while January
had fewest New product launches 22 only. Interestingly January 2012, despite
being the lowest month in term of New product launches, has the highest per
product yield. February 2012 although being better than January 2012 in new
product launches has the lowest per product yield.
During the period under discussion, May 2012 was the highest month in terms of
sales value but it is the 2nd lowest month after February 2012 in per product
yield.
As evident by above table, more new products were launched in J and A therapeutic
segments which prompts us to think that despite their large size and crowded market
place, there is still potential and growth opportunities which cannot be neglected by the
market players.
-
7/31/2019 Ex- Summary 1st Half 2012
22/51
22
MULTINATIONAL Vs NATIONAL ANALYSIS (SPLY)
The 25 MNCs in Pakistan have a cumulative share of 43.60% in value. The per company
average market share comes to 1.74 %. A historical comparison of MNCs share analysis
over the last five years is shown in the chart below. The graph shows a gradual decline
in share of MNCs with balance of power clearly shifting in favor of National companies.
During 2012, MNCs have lost 1.07% in value while in units, they have lost .79%. Main
segments where national companies have gained are J, A and
C class.
The evolution index of MNCs is 97.62 & NATs is 101.92 in the 1st Half of 2012 (MAT
Basis); a yard stick to guage gain or loss of market share. The current market share
of 56.40% in value and 52.64% in units that national companies enjoy in this
-
7/31/2019 Ex- Summary 1st Half 2012
23/51
23
market is through 8,107 Active products (currently available in the market and sales
reported in IMS), whereas MNCs have 43.60% share in value and 47.36% in units
through currently 993 Active products.
DERIVED /REDEFINED MARKET ANALYSIS
As market share analysis is one of the key yardsticks to measure performance, it would
be more pertinent to analyze Corporates in their own competing grounds. As would be
observed below, there are major shifts for some companies creating new ranking
dimensions to corporate listings. The results are tabulated as under:
Searle which was first in term of operating market size during same period last year 1st
half of 2011 is still at no 1 position in 1 st half 2012. The playing area of Searle which was
113 billion has now expanded up to 121 billion and Pfizer stood at 2nd position with 118
billion followed by GSK, Novartis and Barrett Hodgson. Thus, on the basis of the above
and according to redefined market shares, the top 10 corporate rankings in
descending order would be: Roche, Nestle, GlaxoSmithKline, Abbott, Bayer, Sami,
-
7/31/2019 Ex- Summary 1st Half 2012
24/51
24
Sanofi-Aventis, Getz, Novartis and Pfizer. Its interesting to note that although both
Novartis and Getz enjoy same market share in total market but in terms of real market
share Getz clearly surpasses Novartis. Though Nestle is ranked 2 nd in terms of real
market share, however, Nestles sales are mainly from its consumer (non-
pharmaceutical) products.
Per Product YieldThe Per Product Yield for top 20 Corporates is tabulated as under:
GSK, Abbott, Sami, Nestle and Roche are proud members of the club who have achieved
over Rs 100 Mn in per product yield. Sami has created history by becoming the first
national company to be a member of this prestigious club. GSK has got the highest
-
7/31/2019 Ex- Summary 1st Half 2012
25/51
25
number of active products i.e.; 162 while within the top 20, Nestle with 21 products sits
at the bottom of the list.
Top 10 MNCs and Nationals Sales and Market share
GSK leads the MNCs with highest sales and the only corporate with double
digit market share. At Nationals front top 5 Companies each have greater
than 2% share from total market. Top 10 Nationals occupy nearly of
the total industry sales (23.03%).
-
7/31/2019 Ex- Summary 1st Half 2012
26/51
26
ACTIVE MARKETA fair idea could be extracted from the following table, where the top 20 ATCs are analyzed under corporat
contribution (Multinational & National), formulation and number of brands available.
Of the 20 TCs analyzed, the honors are nearly equally shared by MNCs and Nationals as MNCs
dominate in 7 ATCs while Nationals dominate in the rest 13. M01A has highest no of products,
making it the toughest battle ground among the leading segments. A few ATCs level III worth
mentioning which have clear cut MNC domination are J01C-BROAD SPECTRUM PENICILLIN(81.76), N02B-NON-NARCOTIC ANALGESICS (71.43), A12A-CALCIUM (54.47), A11E- VITAMIN B
COMPLEX (81.46), J05B-ANTIVIRALS EXCL. ANTI HIV (56.94) and A10C- HUMAN INSULIN +
ANALOGUES (95.10). Similarly some ATCs level III where Nationals have clear domination are
J01D-CEPHALOSPORINS & COMBINATIONS (77.35), J01G- FLUOROQUINOLONES (76.93), A02B-
ANTIULCERANTS (87.06), P01D-ANTI-MALARIALS (88.17), R05C-EXPECTORANTS (83.70) and
C10A-CHOLESTROL & TRIGLY. REGULATOR (92.36)
-
7/31/2019 Ex- Summary 1st Half 2012
27/51
27
FORMULATION WISE CONTRIBUTION: Whats happening at this front?
The above table shows that Oral solid dominates the market with 50% share for total market
and as well as MNCs and Nationals. Although it has a lions share in all formulation, its growth is
less than the total market and respective segments.
Oral liquid despite being 2nd in market share is growing faster than the total market and MNC/
National segments.
-
7/31/2019 Ex- Summary 1st Half 2012
28/51
28
Corporate Matrix Q2-2012 Performance (MAT BASIS)
*CONT. TO PK.PM = Contribution to Pakistan Pharmaceutical Market
-
7/31/2019 Ex- Summary 1st Half 2012
29/51
29
Top 20 Corporations (Excl. V06 & V07) formulation wise Contribution %
Solid, liquid and Injectable % contribution for the top 20 corporations in total Pharmaceutical
Industry of Pakistan in Q2-2012 on MAT Basis is tabulated as under:
In Solid formulation, GSK is on top position with 5.89% share followed by Getz, Novartis
and Abbott having more than 3% contribution.
In Liquids, GSK again remains on top with 2.77% share followed by Abbott and Pfizer
having more than 1% contribution. Searle and Novartis stand on 4th and 5th positions
respectively.In Injectable market, Sanofi-Aventis is on top position with a share of 1.55% followed by
Sami, Roche and BOSCH with more than 1% contribution.
-
7/31/2019 Ex- Summary 1st Half 2012
30/51
30
Absolute Growth of Top 10 Corporations
Total industry had an absolute growth of Rs 26.23 Bn on MAT Q2-2012 basis and it was Rs
21.68 Bn on MAT Q2-2011. If we analyze the absolute growth of top 10 Corporations
contributed 45.7% of total Absolute growth of the Industry. We come to the conclusion
that in the top 10 corporations, GSK is the first corporate which achieved Rs 2 Bn in
absolute growth followed by Abbott which has achieved 1.94 Bn and another 3 Corporateshave crossed One billion plus in absolute growth. As can we seen below that two National
Corporates are in pursuit of reaching/surpassing the two MNC giants in term of absolute
growth.
Elements of Growth (EGS)
A deep dive into the Elements of growth show that on an average 72% of Absolute Growth is
coming from Volume, 8.36% from New Product launches, 5.29% from Line Extensions while
14.32% from Price change of top 10 Corporates.
-
7/31/2019 Ex- Summary 1st Half 2012
31/51
31
Top 10 Corporations Per Day Yield (January -June 2012)
The table shows PDY (Per Day Yield) of top 10 corporations of the Pakistan Pharma Industry.
Following are the key findings from the table:
Most Productive Month
The average productivity of the Industry per month for the months of January to June 2012
comes to Rs. 516,066,902. The highest productivity is seen in the month of May with Rs.
546,648,523. If we analyze the productivity of individual corporations:
Company Most Productive Month
GSK March
Abbott, Pfizer, Getz & Searle April
Novartis, Sami & Merck May
Sanofi & Hilton June
-
7/31/2019 Ex- Summary 1st Half 2012
32/51
32
Least Productive Month
January was the least productive month for the Industry and as well as for the top 10 Corporates.
Growth Per Day Productivity June / January
If we calculate the growth on per day productivity of Industry for the period June over January it is
17.40%. This calculation in percentage is derived by dividing the per day productivity of
industry in the month of June by the per day productivity in January. For the individual
corporations, Sanofi has the highest growth on per day productivity i.e. (+44.03%) while GSK has
the lowest growth on per day productivity i.e. (0.33%).
-
7/31/2019 Ex- Summary 1st Half 2012
33/51
33
MARKET COMMENTARY (MAT Q2 2012 Vs MAT Q2 2011)
LEADING 20 CORPORATES (DETAIL ON TABLE 1)
The overall market reached 180.083 Bn rupee mark with a growth of +17.03% on MAT
Q2 2012 basis. The top 8 Corporates have crossed 5 billion mark. In the top 20Corporates, 9 are multinationals and 11 are nationals. The top 20 Corporates contribute
62.37% of the total Market. GLAXOSMITHKLINE and ABBOTT were the main contributors
with 10.95% and 6.52% share respectively of the total market.
In the top twenty Corporates ranking the first four Corporates (GSK, Abbott, Pfizer and
Novartis) maintained their rankings. However shift in rank was observed as follows
The Corporates who managed to grow more than the market (having evolution indices
above 100) are ABBOTT, GETZ, SAMI, BOSCH, GLOBAL and ATCO. Amongst the top 20
Corporates, SAMI was the fastest growing company (+30.11%) followed by GETZ
(+28.24%), GLOBAL (+27.48%), and ATCO (+22.31%).
The top 20 Corporates cumulative value is 112.27 billion (62.34% market share) this
year and in 2011 it was 96.96 billion (63.01% market share). If we analyze the growth
contribution from the total Pakistan Pharma market, the top 20 grew 15.79% while rest
of the market grew 19.12% which is higher than the total Pharma market. This slower
growth of the top 20 club made them loose 0.67% market share this year in 2Q 2012
MAT Vs 2Q 2011 MAT.
-
7/31/2019 Ex- Summary 1st Half 2012
34/51
34
LEADING 20 MULTINATIONAL CORPORATES (DETAIL ON TABLE-2)
Although the MNCs grew with double digit +14.24%, they lost around 1.07% share in
value to National companies at MAT Q2 - 2012 as compared to MAT Q2 2011. Total
market size of MNCs moved from Rs. 68.73 Bn to Rs 78.52 Bn. The fastest growing
corporate is ALCON +26.11% followed by JOHNSONS & JOHNSONS +25.14%,
LUNDBECK +22.42% and NOVO NORDISK +19.04%.
Within the top 20, movements in slots in last one year MAT Q2 2012 Vs MAT Q2 2011
are as follow:
-
7/31/2019 Ex- Summary 1st Half 2012
35/51
35
LEADING 20 NATIONAL CORPORATES (DETAIL ON TABLE-3)
The National Corporates are consistently gaining market share in the Pakistan
Pharmaceutical Industry, owing to their higher than market growth i.e. +19.28% Vs
+17.03% (MAT Q2 2012). The Nationals have a value of Rs. 101.56 billions with a share
of 56.40% with an increase of 1.07% as compared to same period last year. The top 5
slots remained in the same hands while there were some shifts in other Corporates
rankings.
In top 20s club, we saw 5 National corporations improve their ranking this year Vs last
year while 5 corporations on the other hand have slipped down their ranks during the
same period.
Within the top 20, movements in slot in last one year MAT Q2 2012 VsMAT Q2 2011 are
as follows:
Amongst the top 20 Nationals, the fastest growing was SAMI (+30.11%) followed by
PHARMEVO (+28.75%), GETZ (+28.24%), HIGH-Q INTL (+28.0%) and GLOBAL
(+27.48%)
-
7/31/2019 Ex- Summary 1st Half 2012
36/51
36
LEADING 20 ATCs (DETAIL ON TABLE-4)
In the top 20 ATCs, J01D - CEPHALOSPORINS & COMBINATION remained on top of the
list with 14.81 Billion sales and growing at a rate of 14.77%. The next six (6) ATCs have
all crossed the MAT sales of five billion rupees. The top 2 ATCs remained in the sameposition while INFANT FORMULAS, NON-NARCOTIC ANALGESICS, ANTIHISTAMINES
SYSTEMIC and ANTI-EPILEPTICS have retained their ranking while rest of the ATCs that
underwent rank movements are:
Amongst the top 20 ATCs, 9 had faster growth than the total market. The fastest
growing ATC was R05C-Expectorants +29.32% followed by A10C-HUMAN
INSULIN+ANALOUGES +26.06%, P10D-ANTI-MALARIALS +25.30%, A02B-
ANTIULCERANTS +22.51% and A12A-CALCIUM +21.57%. All the ATCs had positive and
double digit growth.
-
7/31/2019 Ex- Summary 1st Half 2012
37/51
37
Where is the growth coming from for the above mentioned 5
fastest growing ATCs?
Despite observing new launches and periodic price increase (hardship cases + using the
price cushion), volume change is the main growth driver for these ATCs. R05C has
observed Price Change as the major component of growth where we have seen
significant price increases as described above.
-
7/31/2019 Ex- Summary 1st Half 2012
38/51
38
LEADING 20 PRODUCTS (DETAIL ON TABLE-5)
AUGMENTIN with sales of 3.27 billion is heading the leading top 20 products table. It is ahead
of the next product in the list by a very big margin of 1.83 billion and has a growth of
+8.54%. It has 1.82% share from total Pakistan Pharma market. Again, the Multinationals
are leading the top 20 products list with 15 products against 5 products of Nationals.
Among the leading 20 products, 6 products belong to GSK, 3 products belong to Abbott and 2
products belong to Sami. The top 20 products contributed 13.59% of the total market.
Among the top 20, highest growth was seen in CAC 1000 Plus +120.38%, ENSURE
+40.56%, PANADOL +36.25%, RISEK +34.62%, OXIDIL +31.35% and NOVIDAT +30.93%
followed by HUMULIN 70/30 +27.87%. In the top 20, 16 products show double digit growth.
Among the leading 20 products, 7 belong to ANTI-INFECTIVE class, 5 belong to ALIMENTARY
TRACT SYSTEM and 3 belong to NON-NARCOTIC ANALGESICS.
LEADING 20 NEW PRODUCTS (DETAIL ON TABLE-6)
National Companies have a major dominance in the new product market (product < 25
months old). Thirteen (13) out of the top 20 new products belong to National companies and
Seven (7) belong to Multi-National
PEG-INF is the leading product with a sales value of Rupees 323.5 million and having
04.12% share from the total new products market. PEG-INF has set a new record and has
raised the bar very high for future new products. We feel that it would be difficult for a new
product to beat this record in near future. In terms of market share within new products,
PREVENAR 13 of PFIZER has 03.85%, UNIPEG of GETZ has 02.68% and OSNATE-D of AGP
has 01.53% occupying the next three positions.
-
7/31/2019 Ex- Summary 1st Half 2012
39/51
39
LEADING 20 SINGLE MOLECULES (DETAIL ON TABLE-7)
The single molecule market reached at Rs. 120 Billion mark having share of 67% with a
growth of +15.81% which is lower than the total market growth in MAT Q2 2012. In this
semester 8 out of top 20 single molecules crossed Rupees 2 billion mark with the
addition of 1 molecule in this club while all top 20 single molecules have crossed the
Rupees 1 billion mark.
Among the top 20, only CEFTRIAXONE, CEFIXIME, OMEPRAZOLE, PARACETAMOL,
AMOXICILIN, PEGINTERFERON ALFA-2A, CLARITHROMYCIN, and AMLODIPINE
maintained their ranks, while significant changes were seen in the ranking of the
remaining molecules as shown in the table below:
-
7/31/2019 Ex- Summary 1st Half 2012
40/51
MEDICAL INDEX OF PAKISTAN (MIP) FACTS
BASED ON MAT JUNE 2012
CONSULTATIONS
The total number of consultations in Pakistan is 802 million on MAT June
2012 and if we analyze top 10 consultations we observed that they alone
contribute 33.92%. In top 10 consultations we observed 80% are coming
from Acute and 20% are from chronic therapeutic class areas.
LEADING 10 CONSULTATION IN PAKISTAN
1. FEVER UNSPECIFIED2. ESSENTIAL (PRIMARY) HYPERTENSION3. DIARREOHA & GASTROENTERITIS OF PRESUMED INFECTIOUS
ORIGIN
4. MALAISE AND FATIGUE5. COUGH6. OTHER SPEC RESPIRATORY DISORDERS7. NAUSEA AND VOMITING8. UNSPECIFIED DIABETES MELLITIS WITHOUT COMPLICATIONS9. URINARY TRACT INFECTION UNSPECIFIED10. ACUTE TONSILLITIS UNSPECIFIED
In the leading 10 consultations in Pakistan, Unspecified Diabetes
Mellitis without complications goes 1 position up (from 9 to 8
position) as compared to last semester (Q4-2011)
-
7/31/2019 Ex- Summary 1st Half 2012
41/51
41
PRESCRIPTIONS
The total prescriptions from all doctor specialties in Pakistan are 1.460 Bn
on MAT June 2012 in which MNCs have 51.69% and Nationals have
48.31% share. This is interesting to note that although MNCs have lost
significant share to National in sales but they are maintaining lead in Rx.
If we analyze total MNCs prescriptions the top ten MNCs share is 95.89
and within total National prescriptions, the top ten Nationals have 48.51%
share.
LEADING 10 CORPORATES IN PAKISTAN
The leading 10 Corporates contribute 861 Mn prescriptions and their
share is 58.95% on MAT June 2012 basis of total Pakistan prescriptions.
1. GlaxoSmithKline2. Abbott3. Pfizer4. Sanofi Aventis5. Novartis6. Searle7. Sami8. Getz9. Merck10. Hilton
6 out of 10 Corporates i.e., 60% Corporates are MNCs again showing
supremacy at this front.
-
7/31/2019 Ex- Summary 1st Half 2012
42/51
42
FASTEST GROWING CORPORATES IN PAKISTAN
If we analyze the fastest growing Corporates in terms of prescriptions in
Pakistan, Nationals are growing faster than MNCs and in top 5 Corporates
4 belong to National and one belongs to MNC, which are:
1. Atco2. Bosch3.Helix4.Servier5.Asian Continental
PRODUCT PRESCRIBED SPECIALITY WISE
An in depth analysis of specialties in terms of their prescribing habits
shows that GPs are prescribing PANADOL as the no 1 drug followed by
CALPOL on second place and AUGMENTIN on third place.For prescribing habits of other specialties please refer to the chart below:
Out of the brands occupying first 3 positions an all doctor specialties, 12
belong to MNCs and 5 belong to Nationals.
-
7/31/2019 Ex- Summary 1st Half 2012
43/51
43
TABLES
TABLE 1-TOP 20 CORPORATES
TABLE 2-TOP 20 MULTINATIONAL CORPORATES
TABLE 3-TOP 20 NATIONAL CORPORATES
TABLE 4-TOP 20 THERAPEUTIC CLASSES
TABLE 5-TOP 20 SINGLE MOLECULES
TABLE 6-TOP 20 LEADING PRODUCTS
TABLE 7-TOP 20 NEW PRODUCTS
-
7/31/2019 Ex- Summary 1st Half 2012
44/51
-
7/31/2019 Ex- Summary 1st Half 2012
45/51
45
-
7/31/2019 Ex- Summary 1st Half 2012
46/51
46
-
7/31/2019 Ex- Summary 1st Half 2012
47/51
47
-
7/31/2019 Ex- Summary 1st Half 2012
48/51
48
-
7/31/2019 Ex- Summary 1st Half 2012
49/51
49
-
7/31/2019 Ex- Summary 1st Half 2012
50/51
50
-
7/31/2019 Ex- Summary 1st Half 2012
51/51
EXECUTIVE SUMMARY 1ST HALF 2012
Feedback form
Dear Client:
We are pleased to present you the Executive Summary 1ST Half 2012 report.
Your valuable feedback on our earlier reports has helped us incorporateseveral new analyses in the subsequent reports.
We request you to provide your feedback and rate the report on the followingparameters.
Parameter Excellent Very Good Good Average Poor
Content of thereport
Presentation style
Value addition toyour work
Suggestions aremost welcome
Please address this page to Mr. A.G. Meghany and fax it back to us on 92-21-34314651
From:
Name & Designation: __________________________________
Company: __________________________________